An in vivo self-assembled central nervous system targeting system for the treatment of diabetes
By self-assembling the central targeting system in vivo, the fusion protein encoded by recombinant plasmids can be used to target the central nervous system, solving the long-term relief and tumorigenic risk problems of diabetes treatment, and achieving a safe and efficient glycemic lowering effect.
Patent Information
- Application Number
- CN202410897716.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-05
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-05
AI Technical Summary
Existing diabetes treatment methods cannot achieve long-term remission of type 2 diabetes, and administration based on fibroblast growth factor (FGF1/FGF4) has problems with tumorigenic risk and low patient compliance.
Develop a self-assembled central targeting system in vivo that encodes fusion proteins based on fibroblast growth factor by recombinant plasmids expressing nucleic acid molecules, including propeptides, central targeting peptides, linking peptides and fibroblast growth factor variants (FGF1ΔHBS) ) to achieve targeting the central nervous system and reduce tumorigenic risk.
The system can pass through the blood-brain barrier by subcutaneous or intravenous injection, achieving a lasting effect of hypoglycemia for at least 13 weeks, avoiding adverse reactions, solving the problems of tumorigenic risk and low patient compliance, and providing long-term effects for the treatment of type 2 diabetes and a secure solution.
Smart Images

Figure CN118421701B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to an in vivo self-assembly central targeting system for treating diabetes, belonging to the technical field of biomedicine and medicine. Background Art
[0002] Diabetes is a group of metabolic diseases characterized by chronic increase in blood glucose levels, mainly including type 1 diabetes and type 2 diabetes. Among them, the main cause of type 2 diabetes is insulin resistance or insufficient insulin secretion caused by various reasons. The clinical manifestations of type 2 diabetes are polyuria, polydipsia, polyphagia, emaciation or weight loss. If blood sugar is not controlled for a long time, it will cause chronic progressive lesions, functional impairment or even failure of tissues and organs such as eyes, kidneys, nerves, heart, and blood vessels, and may cause acute and severe metabolic disorders, ultimately leading to complications such as blindness, amputation and renal failure.
[0003] Many drugs have been used clinically to treat diabetes, but currently, no glucose-lowering drug can cure diabetes. Diabetic patients need to take medication for life, and existing glucose-lowering drugs cannot achieve sustained relief of type 2 diabetes. At present, glucose-lowering drugs used to treat type 2 diabetes mostly need to be administered at least once a day, and the longest-acting drugs on the market, such as semaglutide and telpotide, also need to be injected once a week. Therefore, there is an urgent need to develop a long-term and effective treatment for type 2 diabetes.
[0004] Fibroblast growth factor (FGF) is a family of 22 polypeptides secreted by the pituitary gland and hypothalamus. Studies have shown that several members of the FGF family, including FGF19, FGF21, FGF1, and FGF4, have great potential in the treatment of type 2 diabetes. These FGF members have potent antihyperglycemic effects when administered peripherally, and, notably, single intracerebroventricular (icv) administration of FGF1 and FGF4 can induce sustained diabetic remission in rodents with type 2 diabetes. Therefore, the development of long-term and effective type 2 diabetes therapeutics based on FGF1 and FGF4 is very promising. However, in addition to antidiabetic activity, FGF1 and FGF4 also have mitogenic activity, which makes FGF1 / FGF4 administration a tumorigenic risk, which seriously inhibits the development of type 2 diabetes therapeutics based on FGF1 / FGF4.
[0005] In order to overcome the problem of tumorigenicity of FGF1 / FGF4 administration, further studies have found that the mitogenic activity (i.e., cell proliferation activity) and anti-diabetic activity of FGF1 and FGF4 can be separated, among which the mitogenic activity is mainly induced by FGFR3 and FGFR4, while the anti-diabetic activity is mainly mediated by FGFR1. Therefore, it is possible to reduce its mitogenic properties by developing engineered FGF1 / FGF4 variants to inhibit tumorigenesis. However, whether these FGF1 / FGF4 variants can still maintain long-term anti-diabetic activity in animals has not been tested. In addition, in terms of medication, FGF1 and FGF4 require central injection, and central injection has the problem of low patient compliance. There are also studies trying to develop intranasal delivery systems for FGF1 and FGF4. However, it is not clear whether intranasal delivery is sufficient to provide the same long-term anti-diabetic activity as central injection. Summary of the invention
[0006] To solve the above problems, the present invention provides an in vivo self-assembling central targeting system for treating diabetes, wherein the in vivo self-assembling central targeting system is a recombinant plasmid expressing a nucleic acid molecule; the nucleic acid molecule encodes a fusion protein based on fibroblast growth factor; the fusion protein based on fibroblast growth factor includes a propeptide, a central targeting peptide, a connecting peptide and a fibroblast growth factor variant connected in sequence; the amino acid sequence of the fibroblast growth factor variant is shown in SEQ ID NO.1.
[0007] In one embodiment of the present invention, the amino acid sequence of the propeptide is shown as SEQ ID NO.2.
[0008] In one embodiment of the present invention, the central targeting peptide includes a brain-targeted chimeric rabies virus glycoprotein fragment peptide (RVG), a brain-targeted rabies virus glycoprotein-derived peptide (RDP), a glioma-targeted peptide (Angiopep-2), a transferrin-targeted peptide (THR), a cell-penetrating peptide (Peptide-22) and / or an apolipoprotein E fragment peptide (ApoE(159-167)2); the amino acid sequence of the brain-targeted chimeric rabies virus glycoprotein fragment peptide is shown in SEQ ID NO.3.
[0009] In one embodiment of the present invention, the connecting peptide is a flexible connecting peptide (flexible linker); the flexible connecting peptide includes a GS connecting peptide (GS linker); the amino acid sequence of the GS connecting peptide is shown in SEQ ID NO.4.
[0010] In one embodiment of the present invention, the fibroblast growth factor-based fusion protein consists of a propeptide, a central targeting peptide, a connecting peptide and a fibroblast growth factor variant which are sequentially connected.
[0011] In one embodiment of the present invention, the amino acid sequence of the fibroblast growth factor-based fusion protein is shown in SEQ ID NO.5.
[0012] In one embodiment of the present invention, the vector of the recombinant plasmid is pcDNA6.2-GW / EmGFP-miR plasmid and / or pcDNA3.1 plasmid.
[0013] In one embodiment of the present invention, the method for preparing the recombinant plasmid comprises: linearizing a vector to obtain a linearized vector; and connecting the linearized vector and a nucleic acid molecule to obtain a recombinant plasmid.
[0014] The present invention also provides a fusion protein based on fibroblast growth factor, wherein the fusion protein based on fibroblast growth factor comprises a propeptide, a central targeting peptide, a connecting peptide and a fibroblast growth factor variant (FGF1 non-mitogenic modified body FGF1 ΔHBS ); The amino acid sequence of the fibroblast growth factor variant is shown in SEQ ID NO.1.
[0015] In one embodiment of the present invention, the amino acid sequence of the propeptide is shown as SEQ ID NO.2.
[0016] In one embodiment of the present invention, the central targeting peptide includes a brain-targeted chimeric rabies virus glycoprotein fragment peptide (RVG), a brain-targeted rabies virus glycoprotein-derived peptide (RDP), a glioma-targeted peptide (Angiopep-2), a transferrin-targeted peptide (THR), a cell-penetrating peptide (Peptide-22) and / or an apolipoprotein E fragment peptide (ApoE(159-167)2); the amino acid sequence of the brain-targeted chimeric rabies virus glycoprotein fragment peptide is shown in SEQ ID NO.3.
[0017] In one embodiment of the present invention, the connecting peptide is a flexible connecting peptide (flexible linker); the flexible connecting peptide includes a GS connecting peptide (GS linker); the amino acid sequence of the GS connecting peptide is shown in SEQ ID NO.4.
[0018] In one embodiment of the present invention, the fibroblast growth factor-based fusion protein consists of a propeptide, a central targeting peptide, a connecting peptide and a fibroblast growth factor variant which are sequentially connected.
[0019] In one embodiment of the present invention, the amino acid sequence of the fibroblast growth factor-based fusion protein is shown in SEQ ID NO.5.
[0020] The present invention also provides a nucleic acid molecule, which encodes the in vivo self-assembly central targeting system or the fusion protein based on fibroblast growth factor.
[0021] In one embodiment of the present invention, when encoding the above-mentioned fibroblast growth factor-based fusion protein, the nucleotide sequence of the nucleic acid molecule is as shown in SEQ ID NO.6.
[0022] In one embodiment of the present invention, when encoding the above-mentioned in vivo self-assembly central targeting system, the nucleotide sequence of the nucleic acid molecule is as shown in SEQ ID NO.7.
[0023] The present invention also provides a host cell, wherein the host cell carries the in vivo self-assembly central targeting system; or, the host cell expresses the fusion protein based on fibroblast growth factor; or, the genome of the host cell is integrated with the nucleic acid molecule.
[0024] In one embodiment of the present invention, the host cell comprises Escherichia coli, insect cells, mammalian cells, Bacillus subtilis and / or yeast.
[0025] The present invention also provides the use of the in vivo self-assembly central targeting system or the fusion protein based on fibroblast growth factor or the nucleic acid molecule or the host cell in preparing a drug for treating diabetes.
[0026] In one embodiment of the present invention, the diabetes is type 2 diabetes.
[0027] The present invention also provides a drug for treating diabetes, which comprises the in vivo self-assembly central targeting system, the fusion protein based on fibroblast growth factor, the nucleic acid molecule and / or the host cell.
[0028] In one embodiment of the present invention, the diabetes is type 2 diabetes.
[0029] In one embodiment of the present invention, the drug for treating diabetes further comprises a drug carrier; the drug carrier comprises microcapsules, microspheres, nanoparticles and / or liposomes.
[0030] In one embodiment of the present invention, the nanoparticles comprise lipid nanoparticles (LNPs).
[0031] In one embodiment of the present invention, the drug for treating diabetes is the above-mentioned in vivo self-assembled central targeting system encapsulated by lipid nanoparticles.
[0032] In one embodiment of the present invention, the components of the lipid nanoparticles include ionizable lipids, cholesterol, auxiliary lipids and polyethylene glycol (PEG) lipids; the ionizable lipids include cationic liposomes SM-102; the auxiliary lipids include distearoylphosphatidylcholine (DSPC); and the polyethylene glycol lipids include PEG-DMG-2000.
[0033] The technical solution of the present invention has the following advantages:
[0034] 1. The present invention provides an in vivo self-assembling central targeting system for treating diabetes, wherein the in vivo self-assembling central targeting system is a recombinant plasmid expressing a nucleic acid molecule, wherein the nucleic acid molecule encodes a fusion protein based on fibroblast growth factor, wherein the fusion protein based on fibroblast growth factor comprises a propeptide, a central targeting peptide, a connecting peptide, and a fibroblast growth factor variant (FGF1 non-mitogenic modified body FGF1 ΔHBS ); the amino acid sequence of the fibroblast growth factor variant is shown in SEQ ID NO.1. The fusion protein expressed by this in vivo self-assembling central targeting system places the propeptide in front. Studies have shown that this in vivo self-assembling central targeting system can cross the blood-brain barrier and specifically reach the central nervous system by means other than intracranial injection (subcutaneous injection, intravenous injection), exerting a lasting hypoglycemic effect (at least 13 weeks of sustained and stable hypoglycemic effect) without causing adverse reactions. It not only retains the anti-diabetic activity of fibroblast growth factor, but also avoids the tumorigenic risk of fibroblast growth factor. At the same time, it solves the problem of low patient compliance caused by intracranial injection, provides more ideas for the development of central targeted drugs, and has great application prospects in the treatment of type 2 diabetes.
[0035] 2. The present invention provides a fusion protein based on fibroblast growth factor, wherein the fusion protein based on fibroblast growth factor comprises a propeptide, a central targeting peptide, a connecting peptide and a fibroblast growth factor variant (FGF1 non-mitogenic modified body FGF1 ΔHBS ), the amino acid sequence of the fibroblast growth factor variant is shown in SEQID NO.1. This fusion protein places the propeptide in front. Studies have shown that after integrating this fusion protein into an expression vector to form an in vivo self-assembled central nervous system targeting system, it can cross the blood-brain barrier and specifically reach the central nervous system by means other than intracranial injection (subcutaneous injection, intravenous injection), exerting a lasting hypoglycemic effect (at least 13 weeks of sustained and stable hypoglycemic effect) without causing adverse reactions. It not only retains the anti-diabetic activity of fibroblast growth factor, but also avoids the tumorigenic risk of fibroblast growth factor. At the same time, it solves the problem of low patient compliance caused by intracranial injection, provides more ideas for the development of central nervous system targeted drugs, and has great application prospects in the treatment of type 2 diabetes. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 :Recombinant plasmid pcDNA6.2-p-RVG-FGF1 ΔHBS Plasmid map.
[0037] Figure 2 : Recombinant plasmid pcDNA6.2-p-RVG-FGF1 was injected intravenously ΔHBS Schematic diagram of drug administration to mice with type 2 diabetes.
[0038] Figure 3 : Subcutaneous injection of LNP-encapsulated recombinant plasmid pcDNA6.2-p-RVG-FGF1 ΔHBS Schematic diagram of drug administration to mice with type 2 diabetes.
[0039] Figure 4 :Based on fusion protein (propeptide-RVG-linker-FGF1 ΔHBS ) Effect of drug administration in the treatment of type 2 diabetes.
[0040] Figure 5 :Administration effects of different fusion proteins in the treatment of type 2 diabetes. DETAILED DESCRIPTION
[0041] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.
[0042] If no specific experimental steps or conditions are specified in the following examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be purchased commercially.
[0043] Example 1-1: A fusion protein based on fibroblast growth factor
[0044] This embodiment provides a fusion protein based on fibroblast growth factor (propeptide-RVG-linker-FGF1 ΔHBS ), this fibroblast growth factor-based fusion protein is obtained by sequentially connecting a propeptide, a central targeting peptide, a connecting peptide and a fibroblast growth factor variant, and the amino acid sequence is shown in SEQ ID NO.5.
[0045] Example 1-2: An in vivo self-assembled central nervous system targeting system for treating type 2 diabetes
[0046] This embodiment provides an in vivo self-assembly central targeting system for treating type 2 diabetes. The in vivo self-assembly central targeting system is a recombinant plasmid pcDNA6.2-p-RVG-FGF1 ΔHBS This recombinant plasmid pcDNA6.2-p-RVG-FGF1 ΔHBS Carrying the fusion protein encoding Example 1-1 (propeptide-RVG-linker-FGF1 ΔHBS ) gene, the nucleotide sequence is shown in SEQ ID NO.7 (plasmid map see Figure 1 ).
[0047] The preparation method of the in vivo self-assembled central targeting system for treating type 2 diabetes is as follows:
[0048] The recombinant plasmid for treating type 2 diabetes was constructed using the BLOCK-iT Pol II miR RNAi designer from Invitrogen. The designer provided two DNA oligos sequences, through which the fusion protein (propeptide-RVG-linker-FGF1 ΔHBS ) gene (SEQ ID NO.6) was cloned into the pcDNA6.2-GW / EmGFP-miR linearized vector to obtain a ligation product (this process was completed by GenScript Biotech); the ligation product was transformed into Escherichia coli competent cells DH5α (purchased from Tsingke, TSC01) to obtain a transformation product; the transformation product was streaked on LB agar plate medium (purchased from Thermo Fisher) containing 50 μg / mL ampicillin (Amp), cultured at 37°C for 12 hours, and a single colony was picked; the single colony was inoculated into 3 mL of LB liquid medium (purchased from Thermo Fisher) containing 50 μg / mL spectinomycin, cultured at 37°C for 14 hours to obtain a bacterial solution; the recombinant plasmid in the bacterial solution was extracted and purified for sequencing, and the recombinant plasmid pcDNA6.2-p-RVG-FGF1 was obtained after successful sequencing. ΔHBS This recombinant plasmid pcDNA6.2-p-RVG-FGF1 ΔHBS That is the in vivo self-assembled central targeting system.
[0049] Example 1-3: A LNP drug for treating type 2 diabetes
[0050] This embodiment provides an LNP drug for treating type 2 diabetes. The LNP drug for treating type 2 diabetes is a drug encapsulating the recombinant plasmid pcDNA6.2-p-RVG-FGF1 of Example 1-2. ΔHBSLipid nanoparticles; the lipid nanoparticles are lipid delivery vectors constructed based on four lipid components: cationic liposome SM-102, cholesterol, distearoylphosphatidylcholine (DSPC) and PEG-DMG-2000 (the process of LNP encapsulation of the recombinant plasmid using the four lipid components is carried out by Myanna (Shanghai) Instrument Technology Co., Ltd.).
[0051] Comparative Example 1-1: A fusion protein based on fibroblast growth factor
[0052] This comparative example provides a fusion protein based on fibroblast growth factor (targeting peptide RVG-linker-propeptide-FGF1 ΔHBS ), this fibroblast growth factor-based fusion protein is obtained by sequentially connecting a central targeting peptide, a connecting peptide, a propeptide and a fibroblast growth factor variant, and the amino acid sequence is shown in SEQ ID NO.8.
[0053] Comparative Example 1-2: An in vivo self-assembled central nervous system targeting system for treating type 2 diabetes
[0054] This comparative example provides an in vivo self-assembly central targeting system for treating type 2 diabetes. The in vivo self-assembly central targeting system is a recombinant plasmid pcDNA6.2-RVG-FGF1 ΔHBS , the recombinant plasmid pcDNA6.2-RVG-FGF1 for the treatment of type 2 diabetes ΔHBS Carrying the fusion protein encoding comparative example 1-1 (targeting peptide RVG-linker-propeptide-FGF1 ΔHBS ) of the gene pcDNA6.2-GW / EmGFP-miR plasmid.
[0055] The preparation method of the in vivo self-assembly central targeting system for treating type 2 diabetes is as follows: on the basis of Example 1-1, the fusion protein (propeptide-RVG-linker-FGF1 ΔHBS ) was replaced with the gene encoding the fusion protein of Comparative Example 1-1 (targeting peptide RVG-linker-propeptide-FGF1 ΔHBS ) gene (the nucleotide sequence is shown in SEQ ID NO.9).
[0056] Comparative Example 1-3: A LNP drug for treating type 2 diabetes
[0057] This comparative example provides an LNP drug for treating type 2 diabetes. The LNP drug for treating type 2 diabetes is a recombinant plasmid pcDNA6.2-RVG-FGF1 encapsulated in comparative example 1-2. ΔHBSLipid nanoparticles; the lipid nanoparticles are lipid delivery vectors constructed based on four lipid components: cationic liposome SM-102, cholesterol, distearoylphosphatidylcholine (DSPC) and PEG-DMG-2000 (the process of LNP encapsulation of the recombinant plasmid using the four lipid components is carried out by Myanna (Shanghai) Instrument Technology Co., Ltd.).
[0058] Comparative Example 2-1: A fusion protein based on fibroblast growth factor
[0059] This comparative example provides a fusion protein based on fibroblast growth factor (propeptide-FGF1 ΔHBS -linker-targeting peptide RVG), this fusion protein based on fibroblast growth factor is obtained by sequentially connecting the propeptide, fibroblast growth factor variant, linker peptide and central targeting peptide, and the amino acid sequence is shown in SEQ ID NO.10.
[0060] Comparative Example 2-2: An in vivo self-assembled central nervous system targeting system for treating type 2 diabetes
[0061] This comparative example provides an in vivo self-assembly central targeting system for treating type 2 diabetes. The in vivo self-assembly central targeting system is a recombinant plasmid pcDNA6.2-FGF1 ΔHBS -RVG, the recombinant plasmid pcDNA6.2-FGF1 for the treatment of type 2 diabetes ΔHBS -RVG is a fusion protein carrying the coding of Comparative Example 2-1 (propeptide-FGF1 ΔHBS -linker-targeting peptide RVG) gene of pcDNA6.2-GW / EmGFP-miR plasmid.
[0062] The preparation method of the in vivo self-assembly central targeting system for treating type 2 diabetes is as follows: on the basis of Example 1-1, the fusion protein (propeptide-RVG-linker-FGF1 ΔHBS ) was replaced with the gene encoding the fusion protein of Comparative Example 2-1 (propeptide-FGF1 ΔHBS -linker-targeting peptide RVG) gene (the nucleotide sequence is shown in SEQ ID NO.11).
[0063] Comparative Example 2-3: A LNP drug for treating type 2 diabetes
[0064] This comparative example provides an LNP drug for treating type 2 diabetes. The LNP drug for treating type 2 diabetes is a recombinant plasmid pcDNA6.2-FGF1 encapsulated in comparative example 2-2. ΔHBS-RVG lipid nanoparticles; the lipid nanoparticles are lipid delivery vectors constructed based on four lipid components: cationic liposome SM-102, cholesterol, distearoylphosphatidylcholine (DSPC) and PEG-DMG-2000 (the process of LNP encapsulation of the recombinant plasmid using the four lipid components is carried out by Myanna (Shanghai) Instrument Technology Co., Ltd.).
[0065] Experimental Example 1: Effects of in vivo self-assembled central nervous system targeting system and LNP drugs on type 2 diabetic mice
[0066] This experimental example provides an experiment on the effects of the in vivo self-assembled central targeting system and LNP drugs on type 2 diabetic mice. The experimental process is as follows:
[0067] Experiment 1: Effects of in vivo self-assembled central targeting system and LNP drugs on type 2 diabetic mice under different drug administration methods
[0068] Forty ob / ob mice (purchased from Jicui Yaokang, weighing ~40 g, 6-7 weeks old) were divided into five groups, including an empty control group (NC-plasmid), an intravenous injection group (IV p-RVG-FGF1 ΔHBS -plasmid), subcutaneous injection group A (SC LNP p-RVG-FGF1 ΔHBS -plasmid), subcutaneous injection group B (SC FGF1 ΔHBS -protein) and intracerebral injection group (ICV FGF1 ΔHBS -protein), 8 mice in each group.
[0069] After the grouping, the empty control group mice were intravenously injected with 10 mg / kg of the empty plasmid (i.e., pcDNA6.2-GW / EmGFP-miR plasmid) once, and the intravenous injection group mice were intravenously injected with 10 mg / kg of the in vivo self-assembled central targeting system of Example 1-2 (recombinant plasmid pcDNA6.2-p-RVG-FGF1 ΔHBS ), the mice in the subcutaneous injection group A were given a single subcutaneous injection of 50 μg of the LNP drug for treating type 2 diabetes of Examples 1-3, the mice in the subcutaneous injection group B were given a single subcutaneous injection of 30 μg of FGF1 protein (FGF1 protein consists of a propeptide and a fibroblast growth factor variant, i.e., SEQ ID NO.2+SEQ ID NO.1), and the mice in the intracerebral injection group were given a single intracerebral injection of 3 μg of FGF1 protein (the drug was dissolved in 100 μL of saline and then injected).
[0070] The principle of intravenous injection is: design a genetic circuit that can express FGF variants, and deliver the genetic circuit into the body through intravenous injection; the genetic circuit that enters the body uses the liver as a bioreactor to express drug proteins; because a central targeting peptide is also expressed in the genetic circuit, the expressed FGF variant has the ability to cross the blood-brain barrier and target the central nervous system, thereby exerting its effect (see Figure 2 ).
[0071] The principle of subcutaneous injection is: using the liver targeting function of LNP, the genetic circuit that can express FGF variants is efficiently delivered to the liver through subcutaneous administration, and the liver is used as a bioreaction generator to express the engineered drug protein; because a fused central nervous system targeting peptide is simultaneously expressed in the genetic circuit, the expressed FGF variant has the ability to cross the blood-brain barrier and target the central nervous system, thereby exerting its effect (see for details). Figure 3 ).
[0072] After the injection, the blood glucose changes of mice were continuously monitored at different time points, and the glucose tolerance test (GTT) test was performed on the mice every week after a single injection of the drug. The GTT test was as follows: glucose (1 g / kg) was intraperitoneally injected into mice that had fasted for 12 hours, and the blood glucose levels were measured immediately before (0 minutes) and 15, 30, 60, and 120 minutes after the intraperitoneal injection of glucose to obtain the GTT test results. The experimental results are shown in Figure 4 and Table 1 (see literature for GTT experiments: ScarlettJM, Rojas JM, Matsen ME, Kaiyala KJ, Stefanovski D, Bergman RN, Nguyen HT,Dorfman MD, Lantier L, Wasserman DH, Mirzadeh Z, Unterman TG, Morton GJ,Schwartz MW. Central injection of fibroblast growth factor 1 inducessustained remission of diabetic hyperglycemia in rodents. Nat Med. 2016 Jul;22(7):800-6.).
[0073] Depend on Figure 4As shown in Table 1, 13 weeks after a single injection of the drug, the fasting blood glucose of the mice in the empty control group was about 148.5 mg / dL, and the GTT peak was about 493.2 mg / dL; the fasting blood glucose of the mice in the intracerebral injection group was about 100.2 mg / dL, and the GTT peak was about 407.4 mg / dL; the fasting blood glucose of the mice in the intravenous injection group was about 95.4 mg / dL, and the GTT peak was about 342.0 mg / dL; the subcutaneous injection group A (SC p-RVG-FGF1 ΔHBS -plasmid) mice had fasting blood glucose of about 103.2 mg / dL and GTT peak of about 317.2 mg / dL; subcutaneous injection group B (SC FGF1 ΔHBS -protein) mice fasting blood glucose was about 147.0 mg / dL, and GTT peak was about 506.4 mg / dL. Direct subcutaneous peripheral administration of FGF1 protein is simple to operate and less invasive, but the effect lasts for a short time (less than one week). Although intracerebral injection can last longer, it is more invasive. The in vivo self-assembled central targeting system (recombinant plasmid pcDNA6.2-p-RVG-FGF1 ΔHBS ) has the dual advantages of peripheral and central administration, which can not only maintain a long-term hypoglycemic effect, but also is easy to operate and less invasive.
[0074] Table 1 GTT test results 13 weeks after a single injection of the drug
[0075]
[0076] Experiment 2: Effects of in vivo self-assembled central targeting system expressing different structural fusion proteins and LNP drugs on type 2 diabetic mice
[0077] Twenty-four ob / ob mice (purchased from Jicui Yaokang, weighing ~40 g, 6-7 weeks old) were divided into three groups, namely intravenous medication group A, intravenous medication group B and intravenous medication group C, with 8 mice in each group.
[0078] After the grouping, the mice in the intravenous injection group A were intravenously injected with 10 mg / kg of the in vivo self-assembled central targeting system of Example 1-2 (recombinant plasmid pcDNA6.2-p-RVG-FGF1 ΔHBS ), the mice in the intravenous injection group B were intravenously injected with 10 mg / kg of the in vivo self-assembled central targeting system of comparative example 1-2 (recombinant plasmid pcDNA6.2-RVG-FGF1 ΔHBS ), the mice in the intravenous injection group C were intravenously injected with 10 mg / kg of the in vivo self-assembled central targeting system of comparative example 2-2 (recombinant plasmid pcDNA6.2-FGF1 ΔHBS-RVG) (the drug was dissolved in 100 μL of normal saline and injected).
[0079] After the injection, the blood glucose changes of mice were continuously monitored at different time points, and the glucose tolerance test (GTT) test was performed on the mice every week after a single injection of the drug. The GTT test was as follows: glucose (1 g / kg) was intraperitoneally injected into mice that had fasted for 12 hours, and the blood glucose levels were measured immediately before (0 minutes) and 15, 30, 60, and 120 minutes after the intraperitoneal injection of glucose to obtain the GTT test results. The experimental results are shown in Figure 5 and Table 2.
[0080] Depend on Figure 5 As shown in Table 2, the fasting blood glucose of mice in the intravenous injection group A was about 102.6 mg / dL, and the GTT peak was about 314.1 mg / dL; the fasting blood glucose of mice in the intravenous injection group B was about 132.3 mg / dL, and the GTT peak was about 368.1 mg / dL; the fasting blood glucose of mice in the intravenous injection group C was about 144.5 mg / dL, and the GTT peak was about 431.6 mg / dL. This result shows that the in vivo self-assembled central targeting system of Example 1-2 is the optimal structural modification method.
[0081] Table 2 GTT test results 13 weeks after a single injection of the drug
[0082]
[0083] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. A fusion protein based on fibroblast growth factor, characterized in that: The amino acid sequence of the fusion protein based on fibroblast growth factor is shown in SEQ ID NO.
5.
2. The fusion protein according to claim 1, characterized in that The fusion protein based on fibroblast growth factor consists of a propeptide, a central targeting peptide, a connecting peptide and a fibroblast growth factor variant which are connected in sequence.
3. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the fusion protein of claim 1 or 2.
4. An in vivo self-assembled central nervous system targeting system for treating type 2 diabetes, characterized in that: The in vivo self-assembly central targeting system is a recombinant plasmid expressing the nucleic acid molecule of claim 3.
5. A host cell, characterized in that The host cell expresses the fusion protein of claim 1 or 2; or, the genome of the host cell is integrated with the nucleic acid molecule of claim 3; or, the host cell carries the in vivo self-assembly central targeting system of claim 4.
6. Use of the fusion protein according to claim 1 or 2, the nucleic acid molecule according to claim 3, the in vivo self-assembly central targeting system according to claim 4, or the host cell according to claim 5 in the preparation of a drug for treating type 2 diabetes.
7. A drug for treating type 2 diabetes, characterized in that: The drug for treating type 2 diabetes comprises the fusion protein according to claim 1 or 2, the nucleic acid molecule according to claim 3, the in vivo self-assembly central targeting system according to claim 4 and / or the host cell according to claim 5.
8. The drug for treating type 2 diabetes according to claim 7, characterized in that: The drug for treating type 2 diabetes also includes a drug carrier; the drug carrier includes microcapsules, microspheres, nanoparticles and / or liposomes.
9. The drug for treating type 2 diabetes according to claim 8, characterized in that: The nanoparticles include lipid nanoparticles; the drug for treating type 2 diabetes is the in vivo self-assembly central targeting system according to claim 4 encapsulated by lipid nanoparticles.
